Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT06505200
Active, not recruiting Observational

Observational Cohort Study Renal Transplantation University Hospitals Leuven

NCT06505200 · tracked via the Priya Life Science Belgium tracker
Sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Observational
Started
2004-03-01
Last updated
2026-05-06

Condition(s) studied

Kidney Transplant RejectionKidney TransplantationKidney Transplant Failure

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

This observational cohort study aims to compile routinely collected clinical, histological and outcome data of kidney transplant recipients, to evaluate risk factors for post-transplant injury, phenotypes of injury, and impact on outcome of such injury, in order to provide clinicians more accurate, less biased and faster tools for diagnosis, clinical management and treatment decisions with regard to kidney transplant rejection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \* All adult kidney transplant recipients transplanted at the University Hospitals Leuven between 01/03/2004 and 01/06/2022, without restrictions with regard to age, sex, underlying kidney disease etc. Exclusion Criteria: \* Patients with combined transplantations (e.g. heart + kidney, liver + kidney, lung + kidney)

Primary outcome measure(s)

  • Kidney transplant failure — 2004 - 2022
    Graft failure, recipient death

Trial sites (1)

FacilityCityRegionStatus
University Hospitals Leuven Leuven Belgium

More Universitaire Ziekenhuizen KU Leuven trials in Belgium

A Study to Investigate the Effect of a Meal At 6pm the Day Before the Colonoscopy on the Bowel Cleansing with Plenvu Active, not recruiting
Follow-up and Outcome of Operative Treatment With Decompressive Release Of The Peroneal Nerve Recruiting
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Recruiting
Cochlear Implantation for Young Single-sided Deaf Children Active, not recruiting
Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt Recruiting

Other trials for the same condition

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation Recruiting
Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch Recruiting
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) Active, not recruiting
Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients Recruiting
Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06505200 on ClinicalTrials.gov ↗ ← All trials in Belgium